International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease.
BACKGROUND
Reflux Questionnaire (ReQuest), a newly developed gastro-oesophageal reflux disease-sensitive scale, can be used to reliably evaluate the effect of treatment on gastro-oesophageal reflux disease symptoms.


OBJECTIVE
International validation of this scale, in patients suffering from endoscopy-negative gastro-oesophageal reflux disease.


METHODS
In this open, multicentre and multinational clinical trial 840 endoscopy-negative gastro-oesophageal reflux disease patients received pantoprazole 20 mg daily for 28 days. The long and short versions of ReQuest were completed both in the pre-treatment and treatment phases. For scale development an item reduction analysis was performed. Internal consistency, test-retest reliability and responsiveness were calculated for psychometric analysis. Construct validity was evaluated by comparison with the Gastrointestinal Symptom Rating Scale and the Psychological General Well-being questionnaire by means of correlation coefficients.


RESULTS
Factor analyses confirmed the content validity of both long and short version of ReQuest. Psychometric calculations proved high internal consistency (Cronbach's alpha: 0.9), test-retest reliability [Intraclass Correlation Coefficient: 0.9 (long vs. long) and 0.8 (short vs. short)], and responsiveness (Responsiveness Index 320.3) of the scale, for which also good construct validity was achieved (correlation coefficient: Gastrointestinal Symptom Rating Scale 0.6; Psychological General Well-being -0.4).


CONCLUSIONS
ReQuest proved valid, reliable, and responsive in this multinational clinical trial to evaluate treatment response in endoscopy-negative gastro-oesophageal reflux disease patients.
Bardhan
K D
KD
District General Hospital, Rotherham, UK. bardhan.sec@rothgen.nhs.uk
Stanghellini
V
V
Armstrong
D
D
Berghöfer
P
P
Gatz
G
G
Mönnikes
H
H
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000328:Adult; D004334:Drug Administration Schedule; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000188:drug therapy*; D005773:Gastroscopy; D006801:Humans; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D011788:Quality of Life; D015203:Reproducibility of Results; D012720:Severity of Illness Index; D016037:Single-Blind Method; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000077402:Pantoprazole